Find Funding Opportunities

COVID-19 Funding Notices | Approved Initiative Concepts | Research Opportunity Announcements
NINDS Interest in Pain Research | View information, FAQs, resources, and available funding notices and opportunities.

All NINDS-related funding opportunity announcements (FOAs), request for applications (RFAs), program announcements (PAs), and other NIH Guide announcements are listed.Search the Closed Announcements tab to find expired opportunities. Search the Notices tab to find all Notices.

Learn more about award types and program directors and managers.

NINDS has a number of open positions for researchers and clinicians to contribute to exciting neuroscience programs - APPLY NOW!

Research Category: Neural Exposome, ONETOXExpiration Date: Thursday, July 7, 2022FOA Number: NOT-AG-22-022Release Date: Wednesday, June 1, 2022Announcement Type: Notice of Special InterestContact: David Jett

The National Institute on Aging (NIA) is issuing this Notice of Special Interest (NOSI) to invite Administrative Supplement applications to existing awards in response to the urgent need for research infrastructure that addresses the role of diverse physical, chemical, social, psychological, and economic exposures across multiple levels and across the life course in the etiology and social disparities of Alzheimer’s disease (AD) and AD-related dementias (ADRD).

Expiration Date: Friday, July 29, 2022FOA Number: RFA-NS-22-067Release Date: Tuesday, May 24, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA) is to invite applications for Phase II SBIR applications to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion (tMCAo)). The PIs of the awarded interventions will become part of the network and will collaborate with the SPAN Coordinating Center (RFA-NS-22-004), testing laboratories (RFA-NS-22-003), and other intervention contributors (RFA-NS-22-066, RFA-NS-22-067) to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. Applicants must propose a research project involving a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.
Expiration Date: Wednesday, July 6, 2022FOA Number: NOT-PM-22-002Release Date: Friday, May 20, 2022Announcement Type: Notice of Special Interest
The All of Us Research Program (All of Us) within the Office of the Director (OD) encourages eligible grantees of the participating Institutes, Centers, and Offices (ICOs) to apply for administrative supplements to support analysis of currently available data within the All of Us Research Programs Researcher Workbench or to develop analysis tools for the available data within the general scope of the parent award.
Expiration Date: Friday, July 29, 2022FOA Number: RFA-NS-22-066Release Date: Monday, May 16, 2022Announcement Type: RFA
The purpose of this funding opportunity announcement (FOA) is to invite applications for research projects to test promising cerebrovascular interventions in the NINDS Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion, tMCAo). The PIs of the awarded interventions will become part of the network and will collaborate with the SPAN Coordinating Center (RFA-NS-22-004), testing laboratories (RFA-NS-22-003), and other intervention contributors (RFA-NS-22-066, RFA-NS-22-067) to facilitate the parallel testing of multiple cerebroprotective interventions in experimental models of ischemic stroke. Applicants must propose a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion.
Expiration Date: Saturday, June 18, 2022FOA Number: RFA-NS-22-071Release Date: Thursday, May 12, 2022Announcement Type: RFA
The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.
Expiration Date: Saturday, July 16, 2022FOA Number: RFA-NS-22-060Release Date: Thursday, May 5, 2022Announcement Type: RFA
There is an urgent need for more research to establish best practices in the pain management field, however, there is a limited workforce pipeline of pain researchers to meet NIHs long-term goals of providing effective non-opioid options for the treatment of pain conditions and better pain management overall. The Interagency Pain Research Coordinating Committee (IPRCC) has identified the workforce problem as a barrier for new pain research, and has identified factors that contributed to it such as barriers to entry into the field of pain research that have constricted growth high departure rate of senior investigators and mentors. The IPRCC also identified a need for more structured opportunities for early-stage investigators to learn from and be mentored by experienced investigators. The pain management field has further recognized that basic, translational, and clinical researchers do not regularly collaborate when developing grant applications. If pain management researchers across all disciplines were to work together, it would enhance the innovation, relevance, and practical application of pain management research. To support the NIH HEAL Initiatives response supporting new investigators, promoting multidisciplinary collaborations among pain researchers, and identifying innovate treatments to manage pain, this FOA invites applications for the Coordinating Center for National Pain Scientists (CCNPS). The CCNPS will be a central facilitator for integrating training and mentoring across a network of mentors and early-stage investigators funded by NIH (e.g., NIH trainees, NIH fellows, and Career Development Awardees). The main purpose of the CCNPS is to enhance the training experience of new pain researchers across the continuum of basic, translational, and clinical research and create a vast network of NIH-funded pain researchers to promote multidisciplinary collaborations in pain research. The CCNPS will create and run a coordination center to connect NIH-fund
Expiration Date: Saturday, July 30, 2022FOA Number: PAR-22-146Release Date: Thursday, April 28, 2022Announcement Type: PAR
This FOA solicits Research Education Grant (R25) applications to develop and implement a short course focused on (1) steps required for successful medical device development, translation, and commercialization (2) common technical and strategic challenges, and (3) best-practices and resources for each stage in the process. Applicants may choose to include an extended mentorship plan if they see fit. The short course should address a broad audience, including senior post-doctoral fellows, independent academic researchers, clinician scientists, and small business entrepreneurs interested in developing, translating, and/or commercializing medical devices to diagnose or treat a nervous system disorder.
Expiration Date: Wednesday, June 1, 2022FOA Number: NOT-OD-22-110Release Date: Friday, April 22, 2022Announcement Type: Notice of Special Interest
The goal of this Notice of Special Interest (NOSI) is to provide support through administrative supplements to strengthen data management, sharing and data readiness efforts within the HEAL Initiative that further fosters collaboration among HEAL awardees and enables maximal data discoverability, interoperability, and reuse by aligning with the FAIR (Findable, Accessible, Interoperable, and Reusable) principles. This NOSI provides an opportunity for existing HEAL Initiative awardees to increase data FAIR-ness, participate in coordinated HEAL Initiative activities to build community around data sharing, and foster sustainability of HEAL Initiative digital assets. This NOSI is soliciting administrative supplements from existing awards funded or supplemented by the HEAL Initiative or otherwise required to meet HEALs Public Access and Data Sharing Policy. Applications from HEAL research teams that are already working with data coordinating centers as requirement of the award must provide justification for applying and will be given lower priority. Sharing HEAL-generated results and associated data as rapidly as possible will allow the broader community to ask and answer new research questions; conduct secondary analyses; and address fast-evolving challenges that surround pain management, opioid use and misuse, and overdose.
Expiration Date: Wednesday, June 1, 2022FOA Number: RFA-OD-22-011Release Date: Wednesday, April 6, 2022Announcement Type: RFA
The NIH Office of the Director intends to support a Rapid Acceleration of Diagnostics (RADx) Tribal Data Repository (RADx TDR) for American Indian and Alaska Native (AI/AN) data collected from projects supported by the RADx initiative. The RADx TDR data will allow better understanding of the impact of COVID-19, support research to better inform and develop policies to address current and future pandemics, and support and promote researchers, including AI/AN researchers.
Expiration Date: Saturday, April 2, 2022FOA Number: NOT-NS-22-001Release Date: Thursday, February 17, 2022Announcement Type: Notice of Special Interest
This NINDS Notice of Special Interest (NOSI) announces the availability of administrative supplements to support examination of human in-vivo magnetic resonance imaging (MRI) findings of presumed vascular origin (vascular contributions to cognitive impairment and dementia, VCID) as they relate to post-mortem pathology of AD/ADRD. Of interest are brain lesions resulting from dysfunctional vasculature or vascular processes, such as white matter hyperintensities, infarcts (including cortical microinfarcts), and microbleeds, along with cellular, molecular, and in-depth post-mortem imaging and pathological data analysis.